Septerna (NASDAQ:SEPN) SVP Sells $532,650.00 in Stock

by · The Cerbat Gem

Septerna, Inc. (NASDAQ:SEPN – Get Free Report) SVP Daniel Long sold 15,000 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $35.51, for a total transaction of $532,650.00. Following the transaction, the senior vice president owned 96,412 shares of the company’s stock, valued at $3,423,590.12. This represents a 13.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Septerna Trading Down 1.4%

SEPN traded down $0.52 during midday trading on Wednesday, hitting $36.05. 357,572 shares of the company traded hands, compared to its average volume of 309,340. The business has a 50 day simple moving average of $28.80 and a two-hundred day simple moving average of $27.23. Septerna, Inc. has a 52-week low of $10.26 and a 52-week high of $37.99. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of -44.51 and a beta of 2.39.

Septerna (NASDAQ:SEPN – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The business had revenue of $26.52 million during the quarter, compared to analysts’ expectations of $16.98 million. Equities research analysts anticipate that Septerna, Inc. will post -1.57 earnings per share for the current year.

Institutional Trading of Septerna

Hedge funds have recently bought and sold shares of the business. Avoro Capital Advisors LLC lifted its position in Septerna by 8.1% during the third quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock worth $25,158,000 after buying an additional 100,000 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Septerna by 6.1% in the 1st quarter. Bank of New York Mellon Corp now owns 58,709 shares of the company’s stock valued at $1,411,000 after buying an additional 3,377 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Septerna in the 1st quarter worth $21,334,000. Swiss National Bank acquired a new stake in shares of Septerna in the 1st quarter worth $531,000. Finally, First Light Asset Management LLC raised its holdings in shares of Septerna by 18.0% during the 1st quarter. First Light Asset Management LLC now owns 732,860 shares of the company’s stock worth $17,611,000 after acquiring an additional 112,049 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research report on Tuesday, April 21st. Raymond James Financial boosted their price target on Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a research report on Monday, June 8th. Zacks Research raised Septerna from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. JPMorgan Chase & Co. raised their price objective on Septerna from $34.00 to $38.00 and gave the company an “overweight” rating in a report on Tuesday, March 24th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $60.00 target price on shares of Septerna in a research note on Tuesday, March 10th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.78.

Read Our Latest Stock Analysis on Septerna

About Septerna

(Get Free Report)

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.

Further Reading